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tate-of-the-Art Paper
he Global Experience With Percutaneous
ortic Valve Replacement
artyn Thomas, MD
ondon, United Kingdom
ranscatheter aortic valve replacement is now a viable option in the treatment of high-risk severe
ymptomatic aortic stenosis. This review describes the current data with this technology and also the
otential for the future role of the technology, including potential ways to yet further improve the
hort- and longer-term results. (J Am Coll Cardiol Intv 2010;3:1103–9) © 2010 by the American
ollege of Cardiology Foundationn
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tymptomatic severe aortic stenosis is a lethal con-
ition with high 2-year mortality. Although surgi-
al aortic valve replacement (SAVR) has excellent
rocedural results in elderly patients, as comorbidi-
ies and “risk” of the patients increase, so both the
rocedural and 1-year outcomes deteriorate (1). In
ddition, between 30% and 50% of patients with
ymptomatic aortic stenosis do not receive SAVR,
ften because they are not referred to a surgeon—
enerally because of concerns about comorbidities
2,3). Therefore it is highly likely that there might
e a hidden population who would benefit from a
ess invasive way of replacing the aortic valve.
ranscatheter aortic valve implantation (TAVI)
llows the aortic valve to be replaced without a
ternotomy, with a beating heart, and without the
eed for routine cardiopulmonary support.
The first TAVI with a balloon expandable de-
ice was performed in 2002 (4), whereas the
elf-expanding system was first used in 2005 (5).
hese 2 devices are now commercially available
n Europe. Both the Edwards-SAPIEN Trans-
atheter Heart Valve (THV) (Edwards Life-
ciences, Irvine, California) (balloon expandable)
nd the Medtronic CoreValve (Medtronic, Min-
rom Cardiovascular Services, Guys and St. Thomas’ Hospital, London,
nited Kingdom. Dr. Thomas is an advisory board member for Edwards
ifesciences and has received research support from Edwards Life-
ciences $10,000 in the last yearf
anuscript received September 8, 2010; revised manuscript received
eptember 27, 2010, accepted October 1, 2010.eapolis, Minnesota) (self expanding system) be-
ame commercially available in 2007.
ascular Access
he least invasive way of performing a TAVI is the
ransfemoral (TF) retrograde approach to the aor-
ic valve (5,6). However, in some patients the
eripheral vasculature is not sufficiently large to
llow the large bore sheaths and catheters to be
sed. In this circumstance the alternative approach
s the transapical (TA) for the Edwards-SAPIEN
HV (Edwards Lifesciences) (7,8) and the subcla-
ian for the CoreValve (9). Further novel ap-
roaches are being developed, such as the transaor-
ic. This approach is in development for both the
dwards-SAPIEN THV and the CoreValve
10,11). It involves direct access to the aortic arch
ia an upper mini-sternotomy and might be useful
n patients with severe respiratory disease or defor-
ities of the left chest, both of which are relative
ontraindications to a mini-thoracotomy of the TA
pproach.
here Is the Procedure Performed?
t is generally agreed that top-quality imaging is
equired to safely perform TAVI. Therefore, the
rocedure should be performed either in a hybrid
heater or in the cardiac catheter laboratory. Per-
orming the procedure in the operating theater
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1104ith a “C arm” is generally not advised. European guidelines
ave recommended that the procedure should be performed
n centers that perform high volumes of SAVR (12). The
.K. recommendations are that TAVI should be performed
n cardiothoracic surgical centers that have the ability to
rovide immediate access to cardiopulmonary bypass and
ther specialized services such as vascular surgery and renal
upport (13).
atient Selection for the TAVI Procedure
atients are selected for TAVI on the basis of their surgical
isk and anatomical suitability. The risk of the patient is
enerally measured by the logistic European System for
ardiac Operative Risk Evaluation (EuroSCORE) (14) or
he Society of Thoracic Surgeons (STS) score (15). Patients
re, broadly speaking, considered suitable if they have a
ogistic EuroSCORE of 20% or an STS score of 10.
he anatomical suitability is decided after a number of
specialized imaging techniques.
These include transthoracic and
transoesophageal echocardiogra-
phy, coronary and peripheral an-
giography, and computed to-
mography scanning from the
aortic root to the common fem-
oral artery. After the risk assess-
ment and the specialized imag-
ing, the patient should be
reviewed by a multidisciplinary
team to decide on the best ap-
proach to the treatment of the
aortic stenosis. Treatment options
include open SAVR, TAVI, or
medical therapy. Both SAVR
nd TAVI might be preceded by coronary intervention or
alloon aortic valvuloplasty (BAV). The BAV has re-
stablished itself as a bridge to TAVI especially in patients
ith poor left ventricular function—the aim being to
mprove function and reduce the risk of the TAVI proce-
ure. In addition, it might be used to treat patients (at least
n the short term) who are not considered suitable for
AVR or TAVI. Finally, BAV might be used when there is
iagnostic uncertainty as to whether the principal cause of
ymptoms is the stenotic aortic valve, such as patients with
oth important aortic stenosis and respiratory disease who
re breathless. Response to BAV in addition to the mea-
urement of pro–B-type natriuretic peptide might be useful
n these circumstances. Coronary angioplasty is generally
imited to those patients presenting with significant angina
r, again, those with poor left ventricular function in an
bbreviations
nd Acronyms
AV  balloon aortic
alvuloplasty
uroSCORE  European
ystem for Cardiac Operative
isk Evaluation
AVR  surgical aortic valve
eplacement
TS  Society of Thoracic
urgeons
A  transapical
AVI  transcatheter aortic
alve implantation
F  transfemoralttempt to optimize function before TAVI. murrent Procedural and Outcome Data for TAVI:
irst-in-Man/Early Feasibility Studies
he first-in-man and early feasibility studies for TAVI
epresent the pioneering work and learning curve of centers
hroughout the world who developed the TAVI technique.
he initial report of the Edwards-SAPIEN TF (Edwards
ifesciences) retrograde approach in 18 patients indicated a
rocedural success rate of only 78% and a 30-day mortality
f 2 of 17 (11.1%) (6). A similar report for the CoreValve
F system (Medtronic) reported a procedural success rate of
4% and a 30-day mortality of 5 of 25 (20%) (5). The
lternative vascular approach (generally with higher-risk
atients) for the 2 devices are the TA approach for the
dwards-SAPIEN Valve and the subclavian approach for
he Medtronic CoreValve. The first TA Report indicated a
0% procedural success rate and 13.6% mortality at 30 days
8). The data for the subclavian approach seem particularly
ncouraging. In 54 patients the procedural success was
00%, procedural mortality 0%, 30-day mortality 0%, and
-month mortality 9.4% (9).
The Partner EU Registry was a pre-CE mark registry in
30 patients (61 TF and 69 TA), which has now reported
8-month outcomes, respectively (16). The 30-day survival
as 92% for the TF approach and 81% for the TA
pproach. Eighteen-month survival was 71% for the TF
pproach and a disappointing 43% for the TA approach.
hese results might at least partly be explained by the higher
isk nature of the TA versus TF patients (logistic Euro-
CORE 33.8% for TA vs. 25.7% for TF). Importantly,
uch of the post-procedural mortality was noncardiac in
ature and related to the comorbidities of the patients.
imilar data from 126 patients in the early CoreValve
Medtronic) experience showed a 30-day survival of 84.8%
nd a 1-year survival of 71.4% (17).
ost Recent Data on Outcomes After TAVI
he most up-to-date data on the clinical outcomes of TAVI
omes from a number of single center reports and multi-
enter and national registries.
rocedural and 30-day outcomes. The largest registry to
eport to date is the SOURCE (SAPIEN Aortic Biopros-
hesis European Outcome) Registry. This is a post–CE-
ark registry reporting on the results of 1,038 patients
ndergoing TAVI with the Edwards-SAPIEN THV (Ed-
ards Lifesciences) (18,19). The Edwards-SAPIEN valve is
urrently commercially available in 23- and 26-mm sizes.
ost of the published reports and presentations for the TF
pproach use the Edwards-SAPIEN valve and require a
2-F or 24-F sheath, and for the TA approach, a 26-F TA
elivery system is used. The commercially available
edtronic CoreValve system is 18-F–compatible, and
uch of the reported CoreValve data is with this system.
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1105Procedural results are now highly acceptable, with a
uccess rate of 95% and a very low on-table mortality rate.
alve embolization rates (aortic and ventricular) are low
0.3%), as are coronary obstruction rates (0.6%). If coronary
bstruction occurs, it is generally due to a native valve leaflet
overing the coronary ostium rather than because of the
evice itself. This complication can often be predicted by
he height and bulkiness of the native leaflets, the “depth” of
he sinuses of Valsalva, and the distance between the leaflets
nd the coronary ostia. Therefore, careful attention should
e paid to the pre-procedural morphology of the native valve
nd to the anatomy of the aortic root and sinuses of
alsalva. This complication seems to be rare and is similar
or both the Edwards-SAPIEN THV (Edwards Life-
ciences) and the Medtronic CoreValve.
The most important potential complication of both the
F and the TA approach is major vascular access site
omplications. With the TF approach, this has been re-
orted in approximately 8% to 13% of cases using the
dwards system. Major vascular access site complications
nclude obstructive dissections with limb-threatening isch-
mia and femoral or iliac rupture. These complications can
ow be managed with vascular occlusion balloons and stents
both covered and uncovered). Permanent pacemaker re-
uirements for the TF and TA approaches with the
dwards-SAPIEN THV are approximately 5% to 7%,
espectively. The incidence of stroke at 30 days is 2.5%,
hich is the same for both TA and TF. The exact
echanisms for these strokes are unclear but might be
ifferent for the 2 approaches. The 30-day mortality for the
AVI population is now in the region of 6% to 10%. In the
OURCE registry, it was 8.5% for the entire population,
.3% for TF, and 10.8% for TA; this most likely reflects the
igher-risk nature of the TA patients rather than an
ntrinsic difference in risk of the 2 techniques (18).SOURCE  SAPIEN Aortic Bioprosthesis European Outcome; TA  transapical; TF  tA similar registry report using the CoreValve system is
he CoreValve Multicenter, Expanded Evaluation Registry
20). This reported 646 patients and 30-day outcomes.
rocedural success was 97%; procedural mortality was 1.5%;
0-day all-cause mortality was 8%; and the combination of
eath, stroke, and myocardial infarction was 9.3%. With
his third-generation 18-F device the vascular complication
ate was low at 1.9%. The incidence of stroke at 30 days was
.9%, and the requirement for a new permanent pacemaker
as only 9.3%. A variety of other registries have reported
he permanent pacemaker mismatch rate as somewhere
etween 18.5% and 42.5% (21–23).
-year outcomes. The 1-year outcomes for cohort 1 of the
OURCE registry have recently been presented and repre-
ent the most up-to-date results with the current Edwards-
APIEN THV technology (Edwards Lifesciences) (24).
he Kaplan-Meier survival curves for the entire cohort, TA
atients, and TF patients are shown in Figure 1. Kaplan-
eier survival rates were 76.1% for the cohort as a whole,
2.1% for the TA patients, and 81.1% for the TF patients.
ost of the deaths between 30 days and 1 year were
oncardiac, as shown in Figure 2, and most likely reflect the
omorbidities of the patients.
The 1-year survival rates for the CoreValve (Medtronic)
ave recently been reported by 4 important European
ational registries (Fig. 3) with survival rates ranging from
1.9% in the 18-F safety and efficacy study (25), 78.8% in
he Italian Registry (21), 79% in the Belgian Registry (22),
nd 81.6% in the U.K. Registry (23).
ummary of Current Outcomes
he TAVI procedure is now maturing and becoming
redictable. One-year survival is more “patient related”
ather than “procedure related.” Patients can be reasonablyFigure 1. 1-Year Survival in the SOURCE Registryransfemoral.
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1106ssured to expect the following outcomes: procedural mor-
ality is very low, stroke risk is 2 to 4%, permanent
acemaker requirement is 4% to 8% with the SAPIEN
HV and 20% to 40% with the CoreValve, 30-day mor-
ality is 6% to 10%, and 1-year survival is80% with the TF
pproach and 70% with the TA approach (the difference
ainly being explained by the differences in comorbidities
f the patients). The only real difference in outcomes
Figure 3. 1-Year Survival for the CoreValve in Various European Registries
Figure 2. Causes of Death Between 30 Days and 1 Year in the SAPIEN AoFr  French; S&E  safety and efﬁcacy.etween the 2 devices is the requirement for permanent
acemaker.
ontext Versus SAVR
uch of the surgical data on high-risk patients concentrates on
npatient outcomes for patients such as octogenarians. Are
here any comparators for the 1-year results of TAVI? The
oprosthesis European Outcome Registry
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1107eipzig group provided data in their paper from 2009 regard-
ng octogenarian patients undergoing SAVR (1) (Fig. 4). The
atients were divided into those with a logistic EuroSCORE
f 10, 10 to 20, or 20. The 30-day survival rates were
imilar for all risk groups, ranging from 89% to 93%. The
attern for 1-year survival was very similar to TAVI and seems
o reflect the risk of the patient rather than the risk with the
rocedure. Mortality rates between 30 days and 1 year for
atients with a logistic EuroSCORE of10 was 2.5% (1-year
urvival, 90%); a score of 10 to 20 was 11.3% (1-year survival,
8%), and for those with a logistic EuroSCORE of 20
potentially a TAVI population) the mortality rate was 21.3%
1-year survival, 69%). Therefore, the gold standard for 1-year
urvival of high-risk (TAVI-type) SAVR might be seen as
9%. Thus the 1-year survival rate for TF TAVI of 80% is
ighly encouraging within this context.
uture Developments of the Devices
he latest iteration of the Edwards valve, the Edwards-
APIEN XT valve with the Novoflex delivery system
Edwards Lifesciences), involves changes for both the TF
nd TA system. The valve has changed from stainless steel
o cobalt-chromium, and the valve leaflet design has been
odified. The Novoflex delivery system is now 18-F for the
3-mm valve and 19-F for the 26-mm valve. This has been
Figure 4. Immediate and 1-Year Results of Surgical Aortic Valve Replacem
Reprinted, with permission, from Leontyev et al. (1). ES  European System fo
pean Outcome; other abbreviations as in Figure 1.chieved by a novel concept of loading/aligning the delivery salloon onto the SAPIEN XT valve in the descending
orta. The new Ascendra TA delivery system (Edwards
ifesciences) is 24-F and has also been made more ergo-
omically friendly. Improvements are also being made to
he Medtronic CoreValve delivery system that should facil-
tate more accurate placement of the device. Multiple new
evices such as the Sadra-Lotus valve and the Direct Flow
alve are in development. The Direct Flow Medical aortic
alve has reported encouraging early results (26).
Two areas where a further improvement might be seen in
he near future are the incidence and outcomes of vascular
omplications and the prevention of stroke. In the
OURCE registry there was an important association
etween the occurrence of a vascular complication and
-year survival for both the TF and TA approaches. The
resence of a vascular complication reduced the 1-year
urvival from 83.9% to 72.2% for the TF approach and from
3.2% to 47.4% for the TA approach (22). Reduction in the
rench size of the Edwards-SAPIEN THV delivery system
hould result in a reduction in vascular complication rates.
n addition techniques and devices are being developed to
educe the incidence of apical bleeding during the TA
rocedure. Both of these advances, one would anticipate,
hould lead to a further improvement in 1-year mortality for
AVI. The incidence of stroke during TAVI remains a
roublesome 2% to 4%. The exact mechanism of these
Octogenarians of Varying Logistic ES
iac Operative Risk Evaluation; SOURCE  SAPIEN Aortic Bioprosthesis Euro-ent in
r Cardtrokes remains unclear but might include traverse of the
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1108ortic arch by large-bore catheters, manipulation of the
ative diseased aortic leaflets, and hemodynamic insult to
he brain during rapid pacing and device deployment. Two
ecent studies have reported “new” magnetic resonance
maging brain lesions in 70% to 80% of patients after TAVI,
lthough this is rarely associated with clinical sequelae
27,28). The long-term consequences of this phenomenon
re unknown. A new device, the Embrella embolic deflector
Embrella Cardiovascular, Inc., Wayne, Pennsylvania), was
sed for the first time during a TAVI case in January 2010.
he device received a CE mark in May 2010, is placed via
he radial artery, and is designed to “deflect” any embolic
aterial away from the cerebral circulation (29). Hopefully
his type of device will lead to a fall in the silent and clinical
ncidence of neurological events after TAVI.
uture Clinical Studies
t is widely recognized that the logistic EuroSCORE and
he STS score are not ideal tools for measuring the pre-
rocedural risk of TAVI. Certainly, for the EuroSCORE
he predicted mortality is grossly overestimated in the
igher-risk patients. Therefore the development of a TAVI
isk score is required. We recently attempted to construct
uch a score with the 1,000 patients in the SOURCE
egistry and 1-year outcomes (30). The EuroSCORE was
ot useful in predicting 1-year outcomes, generating a
-statistic of only 0.6 for TA and 0.55 for TF patients. This
s hardly surprising, because most of the causes of death
etween 30 days and 1 year are noncardiac and are not
aptured in the EuroSCORE. Multivariate analysis was
ore successful but only moderately useful, generating
-statistics of 0.66 for TA and 0.71 for TF patients. The
ost likely reason for this failure to develop a risk score is
hat the numbers of patients required are likely to be much
igher (the EuroSCORE and STS scores are based on
0,000 to 80,000 patients) and also perhaps the correct
actors are not being captured. It is widely recognized that
frailty” plays a part in outcome and any risk score is likely
o require such a measure, along with other clinical param-
ters. To collect data on such large numbers of patients it
ill be necessary to harmonize clinical end points in clinical
tudies. This will be facilitated by the Valvular Academic
esearch Consortium initiative in which experts in the field
ave agreed to standardized definitions of clinical end points
fter TAVI (31).
The most recent clinical study to report was “cohort b”
f the Partner US randomized trial (32). This cohort was
onsidered surgically inoperable and was randomized
etween medical therapy and TAVI. A large proportion
f the medically treated patients received BAV. Despite
his there is a large difference in 1-year all-comers
urvival (the primary end point), with a 69.3% survival in
he TAVI arm compared with a 50.3% survival in theedical arm (p  0.001). These results suggest that
AVI should now be considered the standard of care for
atients deemed unsuitable for routine SAVR. The
esults of “cohort a” (a group of high-risk patients
andomized between SAVR and TAVI with the TF or
A approach) will be reported in 2011.
he Future of the Technology:
here Are We Going and
hen Will the Risk Be Lowered?
nlike new devices in the coronary world (which tend to be
ntroduced into the lower-risk and technically “easy” pa-
ients), TAVI has started in the highest-risk and technically
ost challenging group of patients with aortic stenosis. This
s to some extent appropriate, given that SAVR is an
xcellent gold standard therapy. Selection of the patient
ho is “ideal” for TAVI will be a major challenge. One
mportant “unknown” is the durability of the transcatheter
alves. Given the excellent results of SAVR in low-risk
atients, it is unlikely that TAVI will have a major role in
hese patients for many years given the cost of the devices.
ven if the device is highly effective, proving cost-
ffectiveness under these circumstances will be very difficult.
his dilemma is demonstrated in a “theoretical” manner in
igure 5. In low-risk patients (however risk is measured) it
s unlikely that TAVI will carry a mortality benefit over
AVR. Equally, in very high-risk patients, it seems unlikely
hat TAVI will again have any advantage. Somewhere
etween these 2 opposite ends of the risk spectrum, there
hould be a middle ground where the TAVI procedure has
mortality advantage over SAVR and therefore will prove
o be cost-effective. Finding this patient population is the
urrent challenge of the interventional community.
1 yr
Mortality
Measure of Risk
TAVI
Surgery
The Sweet
Spot!
Figure 5. The “Sweetspot” of Risk for TAVITAVI  transcatheter aortic valve implantation.
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1109onclusions
ranscatheter aortic valve implantation is maturing as an
nterventional technique for the treatment of severe symp-
omatic aortic stenosis. The procedural results are now
redictable, and the “learning curve” can be shortened by
roper training of the multidisciplinary teams. Our cur-
ent challenge is finding the right patient population who
hould undergo the technique. This will be facilitated by the
evelopment of a “TAVI risk score,” which will replace the
ogistic EuroSCORE and the STS score as a measure of risk
or the procedure. This technology is undoubtedly the
iggest advance for patients and the interventional commu-
ity since the onset of drug-eluting stent technology.
eprint requests and correspondence: Dr. Martyn Thomas,
ardiovascular Services, Guys and St Thomas’ Hospital, London
E1 7EH, United Kingdom. E-mail: mttwins@aol.com.
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